Inhibitors of cellular signalling are cytotoxic or block the budded-to-hyphal transition in the pathogenic yeast Candida albicans
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The pathogenic yeast Candida albicans can grow in multiple morphological states including budded, pseudohyphal and true hyphal forms. The ability to interconvert between budded and hyphal forms, herein termed the budded-to-hyphal transition (BHT), is important for C. albicans virulence, and is regulated by multiple environmental and cellular signals. To identify small-molecule inhibitors of known cellular processes that can also block the BHT, a microplate-based morphological assay was used to screen the BIOMOL–Institute of Chemistry and Cell Biology (ICCB) Known Bioactives collection from the ICCB-Longwood Screening Facility (Harvard Medical School, Boston, MA, USA). Of 480 molecules tested, 53 were cytotoxic to C. albicans and 16 were able to block the BHT without inhibiting budded growth. These 16 BHT inhibitors affected protein kinases, protein phosphatases, Ras signalling pathways, G protein-coupled receptors, calcium homeostasis, nitric oxide and guanylate cyclase signalling, and apoptosis in mammalian cells. Several of these molecules were also able to inhibit filamentous growth in other Candida species, as well as the pathogenic filamentous fungus Aspergillus fumigatus, suggesting a broad fungal host range for these inhibitory molecules. Results from secondary assays, including hyphal-specific transcription and septin localization analysis, were consistent with the inhibitors affecting known BHT signalling pathways in C. albicans. Therefore, these molecules will not only be invaluable in deciphering the signalling pathways regulating the BHT, but also may serve as starting points for potential new antifungal therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444 · cited 1×
“…N,N-DimethylsphingosineD Protein kinase C and sphingosine kinase inhibitor Yatomi et al. (1996) Geldanamycin Binds HSP90, tyrosine kinase inhibitor Whitesell et al. (1994) K252AD Protein kinase inhibitor, broad spectrum Kase et al. (1987) ML-7 Myosin light chain kinase inhibitor Saitoh et al.…”
BackgroundGenomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus
Nierman, W. C., Pain, A., Anderson, M. J., Wortman, J. R., Kim, H. S., Arroyo, J., Berriman, M., Abe, K., Archer, D. B., Bermejo, C., et al. (2005) · Nature · doi:10.1038/nature04332 · Cited by 1,391 · cited 2×
“fumigatus clinical isolate strain Af293, from which the Aspergillus genomic sequence has been determined (Nierman et al., 2005), was kindly provided by Dr Kieren Marr, University of Washington, Seattle, WA, USA.”
Candida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055 · cited 1×
“Candida albicans is a major opportunistic pathogen of immunocompromised hosts (Schmidt-Westhausen et al., 1991; Warnock, 2007), as well as a leading cause of nosocomial bloodstream infections, especially in patients with indwelling medical devices (Kojic & Darouiche, 2004; Lynch & Robertson, 2008).”
The distinct morphogenic states of Candida albicans
Sudbery, P., Gow, N., & Berman, J. (2004) · Trends in Microbiology · doi:10.1016/j.tim.2004.05.008 · Cited by 876 · cited 1×
“C. albicans can grow as either budded (yeast-like) or filamentous cells, the latter comprising pseudohyphae and true hyphae (Sudbery et al., 2004).”
BackgroundSaville, S. P., Lazzell, A. L., Monteagudo, C., & Lopez-Ribot, J. L. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.1053-1060.2003 · Cited by 655 · cited 3×
“Both budded and hyphal cells are found at sites of infection, and the ability to undergo the budded-to-hyphal transition (BHT) is important for virulence (Saville et al., 2003).”
InfluentialLeesnitzer, L. M., Parks, D. J., Bledsoe, R. K., Cobb, J. E., Collins, J. L., Consler, T. G., Davis, R. G., Hull-Ryde, E. A., Lenhard, J. M., Patel, L., et al. (2002) · Biochemistry · doi:10.1021/bi0159581 · Cited by 616 · cited 3×
“Fluspirilene (40 mM) Dopamine receptor antagonist Sah & Bean (1994) GW 9662 (130 mM) Peroxisome proliferator-activated receptor antagonist Leesnitzer et al. (2002) ETYA (12 mM) Lipoxygenase, cyclooxygenase inhibitor Salari et al.”
InfluentialHarnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
Steinbach, W. J., Reedy, J. L., Cramer, R. A., Perfect, J. R., & Heitman, J. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1680 · Cited by 313
Identification of Ras farnesyltransferase inhibitors by microbial screening.
Hara, M., Akasaka, K., Akinaga, S., Okabe, M., Nakano, H., Gomez, R., Wood, D., Uh, M., & Tamanoi, F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2281 · Cited by 257 · cited 1×
“…Gliotoxin* Fungal toxin, farnesyltransferase and geranylgeranyltransferase inhibitor Vigushin et al. (2004) Manumycin A Farnesyltransferase inhibitor Hara et al. (1993) U73122* Phospholipase C activation inhibitor Smith et al. (1990) Vinpocetine Phosphodiesterase I inhibitor Hagiwara et al. (1984)…”
Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms
Uppuluri, P., Nett, J., Heitman, J., & Andes, D. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01397-07 · Cited by 228
Alem, M. A. S., & Douglas, L. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.41-47.2004 · Cited by 205 · cited 2×
“Indomethacin, nimesulide and piroxicam were previously shown to have modest effects on C. albicans hyphal formation and biofilm formation (Alem & Douglas, 2004).”
Role of Hyphal Formation in Interactions of Candida albicans with Endothelial Cells
Phan, Q. T., Belanger, P. H., & Filler, S. G. (2000) · Infection and Immunity · doi:10.1128/iai.68.6.3485-3490.2000 · Cited by 181 · cited 2×
“albicans mutants that have defects in the BHT have a reduced ability to become internalized and to cause endothelial cell injury in vitro (Phan et al., 2000), and small-molecule inhibitors of the BHT can protect endothelial cells from C.”
Cruz, M. C., Goldstein, A. L., Blankenship, J., Del Poeta, M., Perfect, J. R., McCusker, J. H., Bennani, Y. L., Cardenas, M. E., & Heitman, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3162-3170.2001 · Cited by 159
Prostaglandin production during growth of Candida albicans biofilms
Alem, M. A., & Douglas, L. J. (2005) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46172-0 · Cited by 91 · cited 1×
“C. albicans cells produce a variety of eicosanoids, which may regulate cell growth, morphogenesis, biofilm formation and virulence (Alem & Douglas, 2005; Noverr et al., 2003).”
Toenjes, K. A., Munsee, S. M., Ibrahim, A. S., Jeffrey, R., Edwards, J. E., & Johnson, D. I. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.963-972.2005 · Cited by 72 · cited 16×
“Localization of the Cdc10p septin protein in YAW2 cells was as described previously (Toenjes et al., 2005), using a Nikon TE200 inverted microscope, a GFP HYQ filter set and a 606 objective.”
InfluentialSelf-citation
Cited by
Targeting Candida albicans filamentation for antifungal drug development
Vila, T., Romo, J. A., Pierce, C. G., McHardy, S. F., Saville, S. P., & Lopez-Ribot, J. L. (2017) · Virulence · doi:10.1080/21505594.2016.1197444 · Cited by 174
“identified 5 novel small molecules and 16 molecules with known mammalian targets.(61,62) These known compounds were inhibitors of protein kinases, protein phosphatases, Ras signaling pathways, G protein-coupled receptors, cal-”
BackgroundIn Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections
Wong, S. S. W., Kao, R. Y. T., Yuen, K. Y., Wang, Y., Yang, D., Samaranayake, L. P., & Seneviratne, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085836 · Cited by 107
“A handful of small molecules have been reported to possess activity against C. albicans [29, [44] [45] [46] [47] .”
BackgroundNitric Oxide Releasing Nanoparticles for Treatment of Candida Albicans Burn Infections
Macherla, C., Sanchez, D. A., Ahmadi, M. S., Vellozzi, E. M., Friedman, A. J., Nosanchuk, J. D., & Martinez, L. R. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00193 · Cited by 70
Midkiff, J., Borochoff-Porte, N., White, D., & Johnson, D. I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025395 · Cited by 44
Self-citation
Metadata
- Authors
- Toenjes, K. A., Stark, B. C., Brooks, K. M., & Johnson, D. I.
- Venue
- Journal of Medical Microbiology
- Publisher
- Microbiology Society
- Published
- 2009-06-01
- Volume
- 58
- Issue
- 6
- Pages
- 779-790
- ISSN
- 0022-2615 (ISSN-L)
- 1473-5644
- OpenAlex
- W2120895792
- Cited by
- 37
- References
- 15
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.